Epidemiology and 10-year clinical care of juvenile myasthenia gravis in England: a retrospective cohort study
This study confirms the rarity of JMG in England, with steady incidence and prevalence rates over a decade. Further research is required to assess unmet needs in JMG therapy and the importance of effective treatments for this condition.
Authors
- Frank Tennigkeit
- Ali Abbasi (ORCID: https://orcid.org/0000-0002-6452-4765)
- Kerina Bonar
- Piotr Zaremba
- Sigrid Nilius
- Saiju Jacob (ORCID: https://orcid.org/0000-0003-0037-454X)
- Anna Scowcroft (ORCID: https://orcid.org/0000-0002-4727-9243)
- Sithara Ramdas (ORCID: https://orcid.org/0000-0003-3790-2190)
Institutions
- John Radcliffe Hospital (GB)
- University of Oxford (GB)
- UCB Pharma (United Kingdom) (GB)
- NIHR Surgical Reconstruction and Microbiology Research Centre (GB)
- UCB Pharma (Germany) (DE)
- University of Warsaw (PL)
Publication Details
- Journal
- BMJ Neurology Open
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1136/bmjno-2024-001000
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Alexion Pharmaceuticals
- Alnylam Pharmaceuticals
- Regeneron Pharmaceuticals
- Argenx
- Eisai
- Terumo BCT